发明名称 |
RESPONSIVENESS TO ANGIOGENESIS INHIBITORS |
摘要 |
The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene. |
申请公布号 |
ZA201400951(B) |
申请公布日期 |
2015.05.27 |
申请号 |
ZA20140000951 |
申请日期 |
2014.02.07 |
申请人 |
F. HOFFMANN-LA ROCHE AG;VIB vzw;LIFE SCIENCES RESEARCH PARTNERS |
发明人 |
DE HAAS, SANNE LYSBET;LAMBRECHTS, DIETHER;DELMAR, PAUL;SCHERER, STEFAN |
分类号 |
C12Q |
主分类号 |
C12Q |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|